ZA937315B - Anti-arrhythmic analgesically acting phthalazinone derivatives that brea through multi-drug resistance - Google Patents

Anti-arrhythmic analgesically acting phthalazinone derivatives that brea through multi-drug resistance

Info

Publication number
ZA937315B
ZA937315B ZA937315A ZA937315A ZA937315B ZA 937315 B ZA937315 B ZA 937315B ZA 937315 A ZA937315 A ZA 937315A ZA 937315 A ZA937315 A ZA 937315A ZA 937315 B ZA937315 B ZA 937315B
Authority
ZA
South Africa
Prior art keywords
analgesically
brea
arrhythmic
acting
drug resistance
Prior art date
Application number
ZA937315A
Other languages
English (en)
Inventor
Jueren Engel
Ilona Fleischhauer
Peter Metzenauer
Bernhard Kutscher
Stefan Szelenyi
Ulrich Werner
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA937315B publication Critical patent/ZA937315B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA937315A 1992-10-02 1993-10-01 Anti-arrhythmic analgesically acting phthalazinone derivatives that brea through multi-drug resistance ZA937315B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4233113 1992-10-02

Publications (1)

Publication Number Publication Date
ZA937315B true ZA937315B (en) 1994-04-22

Family

ID=6469448

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA937315A ZA937315B (en) 1992-10-02 1993-10-01 Anti-arrhythmic analgesically acting phthalazinone derivatives that brea through multi-drug resistance

Country Status (18)

Country Link
US (1) US5556856A (xx)
EP (1) EP0590551B1 (xx)
JP (1) JP3623975B2 (xx)
CN (1) CN1088435A (xx)
AT (1) ATE144708T1 (xx)
AU (1) AU666773B2 (xx)
CA (1) CA2107548A1 (xx)
CZ (1) CZ199593A3 (xx)
DE (1) DE59304351D1 (xx)
DK (1) DK0590551T3 (xx)
ES (1) ES2096168T3 (xx)
GR (1) GR3022070T3 (xx)
HU (1) HUT65353A (xx)
MX (1) MX9306120A (xx)
RU (1) RU2106143C1 (xx)
SK (1) SK104493A3 (xx)
UA (1) UA26953C2 (xx)
ZA (1) ZA937315B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162616A (en) * 1997-04-16 2000-12-19 Millennium Pharmaceuticals, Inc. Multidrug resistance-associated polypeptide
US7151102B2 (en) 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2005508990A (ja) * 2001-11-07 2005-04-07 ファルマシア・コーポレーション 真核細胞におけるポリアミドの取込みおよび核蓄積を促進する方法
JP4500161B2 (ja) 2002-04-30 2010-07-14 クドス ファーマシューティカルズ リミテッド フタラジノン誘導体
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
GB0419072D0 (en) 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0428111D0 (en) * 2004-12-22 2005-01-26 Kudos Pharm Ltd Pthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
DE602007010118D1 (de) * 2006-04-20 2010-12-09 Glaxo Group Ltd 2-substituierte 4-benzylphthalazinonderivate als histamin-h1- und h3-antagonisten
US20090209520A1 (en) * 2006-06-15 2009-08-20 Kudos Pharmaceuticals Limited 2 -oxybenzamide derivatives as parp inhibitors
CN101484436A (zh) * 2006-06-15 2009-07-15 库多斯药物有限公司 作为parp抑制剂的2-氧基杂芳基酰胺衍生物
JP2009539963A (ja) * 2006-06-15 2009-11-19 クドス ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤
TWI404716B (zh) 2006-10-17 2013-08-11 Kudos Pharm Ltd 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物
ES2341813T3 (es) * 2006-12-20 2010-06-28 Glaxo Group Limited 4-bencil-1 (2h)-ftalazinonas como antagonistas del receptor h1.
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) * 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) * 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
AU2008299721A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
JP2011500537A (ja) * 2007-10-11 2011-01-06 グラクソ グループ リミテッド Ｈ１受容体アンタゴニストとしてのフタラジンおよびピリド［３，４−ｄ］ピリダジン化合物
CN101821242B (zh) 2007-10-17 2013-07-24 库多斯药物有限公司 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
CN102238945B (zh) * 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
TW201114756A (en) * 2009-07-15 2011-05-01 Astrazeneca Ab Phthalazinone compound
CA2906008C (en) 2013-03-13 2019-07-09 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222191B1 (de) * 1985-11-11 1991-01-30 ASTA Pharma AG 4-Benzyl-1-(2H)-phthalazinon-Derivate
JPH0667844B2 (ja) * 1987-03-06 1994-08-31 エーザイ株式会社 虚血性心疾患の治療・予防剤
US5110814A (en) * 1989-01-11 1992-05-05 Asta Pharma Ag Azelastine and its salts used to combat psoriasis

Also Published As

Publication number Publication date
EP0590551A2 (de) 1994-04-06
DE59304351D1 (de) 1996-12-05
RU2106143C1 (ru) 1998-03-10
EP0590551B1 (de) 1996-10-30
AU4876993A (en) 1994-04-14
ES2096168T3 (es) 1997-03-01
SK104493A3 (en) 1994-08-10
MX9306120A (es) 1994-04-29
ATE144708T1 (de) 1996-11-15
CA2107548A1 (en) 1994-04-03
JP3623975B2 (ja) 2005-02-23
HUT65353A (en) 1994-05-02
DK0590551T3 (da) 1997-04-21
EP0590551A3 (xx) 1994-08-31
HU9302784D0 (en) 1993-12-28
US5556856A (en) 1996-09-17
GR3022070T3 (en) 1997-03-31
CN1088435A (zh) 1994-06-29
CZ199593A3 (en) 1994-04-13
AU666773B2 (en) 1996-02-22
JPH06312928A (ja) 1994-11-08
UA26953C2 (uk) 1999-12-29

Similar Documents

Publication Publication Date Title
ZA937315B (en) Anti-arrhythmic analgesically acting phthalazinone derivatives that brea through multi-drug resistance
DE3778734D1 (de) Dibenzo(b,e)oxepin-derivate sowie antiallergische und entzuendunghemmende mittel.
FI894633A0 (fi) Foerfarande och anordning och presspassdon foer framstaellning av en fast, taet roerkoppling.
FI944204A (fi) Kondensoidut indolijohdannaiset, kuten 5HT4-reseptoriantagonistit
FI901148A0 (fi) Tetrahydrokinolinderivat som aer anvaendbara vid vaord av neurodegenerativa stoerningar.
DK330789A (da) Substituerede 1,7-annellerede 1 h-indazoler
NO894539L (no) Fremgangsmaate for fremstilling av nye 2'-halomethyliden-,2'-ethenyliden- og 2'-ethynylcytidin-, uriden og guanosinderivater.
NO891191D0 (no) Fremgangsmaate for fremstilling av nye, terapeutisk virksomme catecholderivater.
DE68923131D1 (de) Bohrer, Schleifverfahren und Schleifvorrichtung.
DE3767178D1 (de) Heisshaertbare stoffgemische enthaltend substituierte bicyclo (2.2.1)hept-5-en-2,3-dicarbonsaeureimide und polymaleinimide.
DE68913397D1 (de) Verwendung von 5-heteroaryl- oder 5-arylsubstituierten Imidazo(2,1-a)isochinolinen.
DE69201302D1 (de) Therapeutische zusammenstellungen auf der basis von 1,2-dithiole-3-thionderivaten.
IT1230795B (it) Procedimento per preparare 1,1,1,2 tetrafluoroetano da 1,1 dicloro 1,2,2,2 tetrafluoroetano.
DE58907381D1 (de) Ungesättigte Derivate von 2,2,6,6-Tetramethylpiperidin.
ITGE930024A0 (it) Gruppo elettrochirurgico trequarti,cosiddetto "trocar", con elettrodi bipolari.
DZ1718A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique.
ES2099865T3 (es) Ciclopentanoperhidrofenantreno-17beta-(3-furil)-3-derivados y composiciones farmaceuticas que comprenden los mismos para el tratamiento de trastornos cardiovasculares.
DE3584652D1 (de) 2,2,6,6-tetramethyl-4-piperidinyl-derivate und ihre verwendung als lichtstabilisatoren.
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
NO167807C (no) Analogifremgangsmaate til fremstilling av 3',4'-dinitrogensubstituerte epipodofyllotoksinglukosidderivater.
NO891381D0 (no) Fremgangsmaate for fremstilling av nye fluorfosfonatnukleotidderivater.
NO891025L (no) Fremgangsmaate for fremstilling av nye, terapeutisk aktivesialosylglycerider.
NO894037L (no) Fremgangsmaate for fremstilling av nye 2-metoksykarbonyl-substituerte n,n'-di(trimetoksybenzoyl) piperaziner.
ITPS910013A1 (it) Testa multipla per foratrici, con attivazione esclusiva dei mandrini effettivamente utilizzati.
ITPS910039V0 (it) Testa multipla per foratrici, con attivazione esclusiva dei mandrini effetivamente utilizzati